Page 10 - Shimadzu Journal vol.9 Issue2

INSIGHT from CUSTOMER

Interview 3 Interview with Dr. Noel Zahr
“Our partnership

is a great support to

advance research in oncology”

We interviewed Dr. Noel Zahr from Assistance Publique–Hôpitaux de Pari (AP-HP), Pitié Salpetrière
Hospital in France, for an activity in pharmacology dedicated to improving drug management
(personalized medicine) on the project of ‘Monoclonal antibody pharmacokinetic assay and
evaluation with the “nSMOL” kit and Shimadzu LCMS instrument’ starting in 2018. APHP and
Shimadzu started collaborations since the project started.

Hello Dr. Zahr, thank you very much for of Tociluzumab during Covid-19 epidemic. This method
spending some time for this interview. allowed us to study the rate of passage of tociluzumab
At first, could you outline the research into the brain, and to describe the marked clinical and
and let us know what discovery and biological response of a targeted treatment with
achievement have been made so far? Tociluzumab in a patient with a severe corticoresistant
CNS toxicity of immune-checkpoint in hibitors (ICI) ther-
We were interested by the development of monoclonal apy* . Finally, our main focus of de vel opment is TDM in
2
antibodies assays by mass spectrometry, but we do not oncology. Thanks to this collaboration, we have devel-
have experience in this field. In the early part of this col- oped a method to quantify several simultaneously
laboration, with the help of Shimadzu and nSMOL kit, monoclonal antibodies* .
3
we were able to develop quickly the dosage of
*1 Zahr, N., Amoura, Z., Beaulieu, Q., Llopis, B., Pha, M., Benameur, N., Mathian A.
Belimumab by LCMS-8060 for patients with systemic & Funck-Brentano, C. (2021) “Application and validation of LC-MS/MS bioanaly-
lupus erythematosus* . Currently, we are in the process sis of Belimumab in patients with systemic lupus erythematosus”, Fundamental &
1
Clinical Pharma cology, 35 (S1) , 144.
of analyzing the results to study the pharma cokinetics *2 article accepted in Neuroimmunology and Neuroin flammation Journal

*3 Data issues from these developments are not published yet.
and pharmacokinetics/pharmaco dy nam ics correla tion
for this drug. Then, we urgently developed the dosage
Dr. Noel Zahr in front of his LCMS-8060

Shimadzu Journal vol.9 Issue2 43